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Primary bone lymphoma (PBL) is a rare but distinct clinicopathological disease. Because it is not common, the
optimal treatment strategy has not been established. Here, we present a patient with PBL of the left radius and
review the related literature. We focus on the standard treatment for PBL. Many aspects such as rehabilitation, local
control and overall survival need to be considered. Studies on this disease should be carried out to clarify the
optimal treatment in the future.
Keywords: Bone lymphoma, Chemotherapy, RadiotherapyBackground
Primary bone lymphoma (PBL) is a distinct disease.
Here, we present a patient with PBL who received com-
bined therapy with radiotherapy, chemotherapy, surgery
and rituximab. Additionally, related reports of PBL are
reviewed. Further studies are needed to establish the
standard strategy for PBL.
Case presentation
A 53-year-old man presented at the First Hospital of
Jilin University (Changchun, China) in December 2011
with a history of progressive pain of the left wrist for
about 2 months. The X-ray radiograph of the left upper
extremity showed a large osteolytic lesion of the distal
radius (Figure 1). The bone biopsy from another hospital
revealed B cell non-Hodgkin lymphoma. The immuno-
chemistry showed: LCA(+), CD20(+), BCL-2(slightly +),
CD79a(−), CD3(−), CD43(−), CD56(−), CD138(−), CD38
(−), κ(−), λ(−) and Ki-67(70%+). The patient then went
to the tertiary hospital for consultation of the pathologic
results. The definitive diagnosis was diffuse large B cell
lymphoma, derived from active B cells out of the germi-
nal center. The immunochemistry revealed: CD10(−),
BCL6(+), MUM-1(+), CD5(−) and cyclin D1(−). Positron
emission tomography-computed tomography (PET/CT)* Correspondence: lijie200461@126.com
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in the distal left radius and no focal uptake in other sites
(Figure 2). The patient did not have fever, night sweats,
pruritus or weight loss.
Laboratory investigations demonstrated a normal complete
blood cell count and a generally normal serum biochem-
ical profile. β2 microglobulin was 2.30 mg/L. Erythrocyte
sedimentation rate was 17 mm/h. Lactate dehydrogenase
was normal. The bone marrow aspiration did not find
neoplastic involvement. Thus, a primary bone lymphoma,
Ann Arbor stage I, International Prognostic Index score 0,
was diagnosed.
First, the patient received radiotherapy. When the dose
reached 28 Gy/14 f, we gave a cycle of concurrent
chemotherapy of rituximab, cyclophosphamide, vincris-
tine and prednisone (R-COP), and the fraction dose was
reduced to 1.5 Gy. The total dose was 28 Gy/14 f plus
12 Gy/8 f. The patient then received a cycle of single ri-
tuximab. On 1 February 2012, surgery was performed to
remove the tumor at the distal region of the left radius,
and autograft of the fibula was done and then internally
fixed. Thirty radioactive iodines were implanted into
the primary tumor bed during the surgery. The post-
operative PET-CT did not find any intensive focal uptake.
The patient then received a cycle of single rituximab,
rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone (R-CHOP) and CHOP, respectively. To
date, the patient’s condition remains stable and disease-
free survival (DFS) has reached nearly 2 years.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 X-ray radiograph showed a large osteolytic lesion of
the distal region of the left radius.
Figure 2 Pre-therapeutic PET/CT showed intensive FDG uptake
in the distal region of the left radius. FDG, fluorodeoxyglucose;
PET/CT, positron emission tomography-computed tomography.
Liu et al. European Journal of Medical Research 2014, 19:19 Page 2 of 4
http://www.eurjmedres.com/content/19/1/19Discussion
PBL is a rare but distinct clinicopathological entity. It ac-
counts for approximately 5% of all non-Hodgkin lymph-
omas and 3% of all primary bone tumors [1]. Because it
is not common, many aspects of the diagnosis, manage-
ment and prognosis of this tumor remain controversial.
PBL occurs in a wide spectrum of patients, aged from
1 year and 6 months to 86 years [2], commonly between
20 and 50 years of age, and is more common in males.
Diffuse large B cell lymphoma is the most common
pathological type, accounting for about 80% of PBLs[3-7]. The most frequent sites of involvement in PBL are
the vertebra, pelvis, femur, humerus, skull and rib [3].
Common clinical manifestations include local pain and
swelling [1].
Ford et al. showed that combined modality treatment
(CMT) provided both disease control and survival bene-
fits for PBL compared with single treatment [8]. However,
the role of radiotherapy for advanced PBL was challenged
in a report by Ramadan et al. [3]. The addition of radio-
therapy to chemotherapy for advanced cases reduced the
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should be the standard option for PBL requires more
research. Achemlal et al. reported a case in which ri-
tuximab resulted in remarkable improvement for a
chemo-resistant PBL [9]. Ramadan et al. insisted that
irradiation should be carried out when spinal cord com-
pression or residual tumor after chemotherapy existed,
which seemed that irradiation only played a minor role
[3]. On the contrary, a prospective trial emphasized the
importance of radiotherapy to improve the local control
and recommended a higher dose (40 to 45 Gy) than that
for other types of lymphoma [10]. A retrospective, multi-
center Rare Cancer Network (RCN) study also pre-
sented a good outcome offered by chemoradiotherapy
for early stage of PBL [11]. For a case of PBL of the left
mandible, Bosch-Barrera et al. reported that chemother-
apy (R-CHOP) plus consolidate radiotherapy can result in
tumor-free survival of 28 months [12].
Orthopedic intervention is usually needed for patho-
logic fractures, avascular necrosis, spinal cord compression,
or for lesions of the weight-bearing bones compromising
stability or joint motion. The potential for long-term
survival suggests the use of implants and techniques
that have the best chance of long-term control [13]. In
our case, concurrent radiotherapy and chemotherapy were
given to rapidly eliminate the tumor. However, patho-
logical fracture did happen and we had to remove the
tumor surgically. Autograft of the fibula was done and
then internally fixed.
PBL has a favorable prognosis over patients of sys-
temic lymphoma with bone involvement. Age is a prog-
nostic factor. The majority of the reports indicate better
survival for patients younger than 60 years, but there are
a few other reports that show better survival in patients
younger than 40 or 50 years [4]. Jawad et al. analyzed
1,500 adult patients with PBL, and pointed out that
younger age and localized disease were independent pre-
dictors of survival [14]. The study also noted that the in-
cidence of the disease has increased during recent years
[14]. Future treatment for patients with PBL needs to be
dependent on strict staging criteria and adherence to
successful published protocols using collaborative clin-
ical trials.
Conclusion
PBL is a rare but distinct clinicopathological entity. Com-
pared with single treatment, CMT can result in both a
good local control rate and survival benefits for local PBL.
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